Table 3.
P30 of Chronic Kidney Disease Epidemiology Collaboration and European Kidney Function Consortium eGFR creatinine, cystatin c, and creatinine–cystatin C equations in the overall study population and by subgroups of race, sex, and age
| Equations | Overall Group | Race Subgroups | Sex Subgroups | Age Subgroups | ||||
|---|---|---|---|---|---|---|---|---|
| Black | Non-Black | Female | Male | <40 | 40–65 | >65 | ||
| N (%) | 4050 (100) | 4050 (100) | 579 (14.3) | 3471 (85.7) | 1557 (38.4) | 2493 (61.6) | 715 (17.7) | 1989 (49.1) |
| Creatinine | ||||||||
| CKD-EPI 2021 (AS) | 86.6 (85.5 to 87.6) | 87.2 (84.5 to 90.0) | 86.5 (85.4 to 87.6) | 83.5 (81.7 to 85.2) | 88.5 (87.2 to 89.8) | 89.4 (87.1 to 91.7) | 87.1 (85.7 to 88.6) | 84.3 (82.3 to 86.3) |
| CKD-EPI 2009 (ASR-NB) | 89.0 (88.0 to 90.0) | 86.4 (83.4 to 89.1) | 89.5 (88.5 to 90.4) | 88.5 (86.9 to 90.0) | 89.3 (88.1 to 90.6) | 90.5 (88.3 to 92.6) | 87.7 (86.2 to 89.1) | 90.2 (88.6 to 91.8) |
| EKFC 2021 (AS) | 90.6 (89.7 to 91.5) | 85.7 (82.7 to 88.5) | 91.4 (90.5 to 92.3) | 91.7 (90.3 to 93.0) | 89.9 (88.7 to 91.1) | 91.6 (89.5 to 93.6) | 88.5 (87.1 to 90.0) | 93.1 (91.8 to 94.4) |
| Cystatin C | ||||||||
| CKD-EPI 2012 (AS) | 88.2 (87.2 to 89.2) | 84.6 (81.7 to 87.6) | 88.9 (87.9 to 89.9) | 88.7 (87.1 to 90.3) | 88.0 (86.7 to 89.2) | 88.3 (85.9 to 90.5) | 86.3 (84.9 to 87.8) | 91.1 (89.5 to 92.6) |
| CKD-EPI 2023 (A) | 86.3 (85.3 to 87.4) | 82.9 (79.8 to 85.8) | 86.9 (85.8 to 88.0) | 84.8 (83.0 to 86.6) | 87.3 (86.0 to 88.6) | 86.0 (83.4 to 88.7) | 84.0 (82.4 to 85.6) | 89.9 (88.2 to 91.5) |
| EKFC 2023 (A) | 88.2 (87.2 to 89.2) | 87.0 (84.3 to 89.6) | 88.4 (87.3 to 89.5) | 87.5 (85.9 to 89.1) | 88.6 (87.4 to 89.8) | 87.0 (84.3 to 89.5) | 86.2 (84.8 to 87.7) | 91.7 (90.1 to 93.1) |
| Creatinine–cystatin C | ||||||||
| CKD-EPI 2021 (AS) | 90.8 (89.9 to 91.6) | 90.5 (88.1 to 92.9) | 90.8 (89.9 to 91.8) | 88.3 (86.7 to 90.0) | 92.3 (91.3 to 93.3) | 93.0 (91.1 to 94.8) | 90.5 (89.2 to 91.9) | 89.9 (88.2 to 91.5) |
| CKD-EPI 2012 (ASR-NB) | 92.2 (91.4 to 93.0) | 90.8 (88.4 to 93.1) | 92.5 (91.6 to 93.3) | 91.5 (90.0 to 92.8) | 92.7 (91.7 to 93.7) | 93.0 (91.0 to 94.8) | 91.4 (90.1 to 92.6) | 93.1 (91.6 to 94.5) |
| EKFC 2023 (AS) | 93.1 (92.3 to 93.9) | 92.7 (90.5 to 94.8) | 93.1 (92.3 to 93.9) | 92.9 (91.7 to 94.2) | 93.1 (92.1 to 94.1) | 92.6 (90.6 to 94.4) | 91.5 (90.2 to 92.7) | 95.6 (94.5 to 96.7) |
P30 (95% CI) was defined as the percentage of individuals with eGFR within 30% of measured GFR. Unit is percent for P30. Higher P30 is optimal. For eGFRcr and eGFRcr-cys, we implemented the EKFC equations using the creatinine Q values for White Europeans and CKD-EPI ASR equations using the NB coefficient for race to avoid specification of race for individual participants. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; A, age; S, sex; R, race; NB, non-Black; EKFC, European Kidney Function Consortium; mGFR, measured GFR.